TY - JOUR
T1 - Epidemiology of liver metastases
AU - Horn, Samantha R.
AU - Stoltzfus, Kelsey C.
AU - Lehrer, Eric J.
AU - Dawson, Laura A.
AU - Tchelebi, Leila
AU - Gusani, Niraj J.
AU - Sharma, Navesh K.
AU - Chen, Hanbo
AU - Trifiletti, Daniel M.
AU - Zaorsky, Nicholas G.
N1 - Funding Information:
DMT reports clinical trial research support from Novocure, publishing fees from Springer Inc, unrelated to the current work. NGZ has startup funding from Penn State Cancer Institute and is supported by the National Institutes of Health LRP 1 L30 CA231572-01. NGZ received personal fees from Springer Nature, Inc and Weatherby Healthcare, unrelated to the current work. NKS receives consultation fees and speaking reimbursement from SIRTEX Medical Inc. LAD reports a licensing agreement with Raysearch, unrelated to the current work. HC is supported by a Fellowship grant from the International Association for the Study of Lung Cancer Foundation. The rest of the authors report no conflicts of interest. NGZ is supported by the National Institutes of Health LRP 1 L30 CA231572-01 and the American Cancer Society, 133738-CSDG-20-013-01-CCE. NGZ received personal fees from Springer Nature, Inc for his textbook Absolute Clinical Radiation Oncology Review.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/8
Y1 - 2020/8
N2 - Aims: The objectives of this study were to (1) characterize the epidemiology of liver metastases at the time of primary cancer diagnosis (synchronous liver metastases), (2) characterize the incidence trends of synchronous liver metastases from 2010−2015 and (3) assess survival of patients with synchronous liver metastases. Methods: The Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 was queried to obtain cases of patients with liver metastases at the time of primary cancer diagnosis. The primary cancers with an incidence rate of liver metastasis >0.1 are presented in this analysis. Results: Among 2.4 million cancer patients, 5.14 % of cancer patients presented with synchronous liver metastases. The most common primary site was breast cancers for younger women (ages 20–50), and colorectal cancers for younger men. As patients get older, a more heterogenous population of the top cancers with liver metastases emerges including esophageal, stomach, small intestine, melanoma, and bladder cancer in addition to the large proportion of lung, pancreatic, and colorectal cancers. The 1-year survival of all patients with liver metastases was 15.1 %, compared to 24.0 % in those with non-hepatic metastases. Regression analysis showed that the presence of liver metastasis was associated with reduced survival, particularly in patients with cancers of the testis, prostate, breast, and anus, and in those with melanoma. Conclusions: The most common primary sites for patients with liver metastases varied based on age at diagnosis. Survival for patients with liver metastasis was significantly decreased as compared to patients without liver metastasis.
AB - Aims: The objectives of this study were to (1) characterize the epidemiology of liver metastases at the time of primary cancer diagnosis (synchronous liver metastases), (2) characterize the incidence trends of synchronous liver metastases from 2010−2015 and (3) assess survival of patients with synchronous liver metastases. Methods: The Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2015 was queried to obtain cases of patients with liver metastases at the time of primary cancer diagnosis. The primary cancers with an incidence rate of liver metastasis >0.1 are presented in this analysis. Results: Among 2.4 million cancer patients, 5.14 % of cancer patients presented with synchronous liver metastases. The most common primary site was breast cancers for younger women (ages 20–50), and colorectal cancers for younger men. As patients get older, a more heterogenous population of the top cancers with liver metastases emerges including esophageal, stomach, small intestine, melanoma, and bladder cancer in addition to the large proportion of lung, pancreatic, and colorectal cancers. The 1-year survival of all patients with liver metastases was 15.1 %, compared to 24.0 % in those with non-hepatic metastases. Regression analysis showed that the presence of liver metastasis was associated with reduced survival, particularly in patients with cancers of the testis, prostate, breast, and anus, and in those with melanoma. Conclusions: The most common primary sites for patients with liver metastases varied based on age at diagnosis. Survival for patients with liver metastasis was significantly decreased as compared to patients without liver metastasis.
UR - http://www.scopus.com/inward/record.url?scp=85086601542&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086601542&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2020.101760
DO - 10.1016/j.canep.2020.101760
M3 - Article
C2 - 32562887
AN - SCOPUS:85086601542
SN - 1877-7821
VL - 67
JO - Cancer Epidemiology
JF - Cancer Epidemiology
M1 - 101760
ER -